文献速递乳腺癌放疗头颈部肿瘤放疗

乳腺癌放疗后甲状腺功能减退风险

Risk of Hypothyroidism in Women After Radiation Therapy for Breast Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2021-01-04

研究纳入2007至2016年接受辅助放疗的4073例乳腺癌女性,比较全乳放疗、Lv.4区域淋巴结照射与锁骨上淋巴结照射后甲状腺功能减退风险;锁骨上淋巴结照射组3年发生率2.2%,显著高于全乳放疗组0.8%,而Lv.4组与全乳放疗组无显著差异。

要点

  • 锁骨上淋巴结照射组3年甲状腺功能减退发生率为2.2%,全乳放疗组为0.8%。
  • Lv.4区域淋巴结照射组3年发生率为0.9%,与全乳放疗组无显著差异。
  • 锁骨上淋巴结照射组甲状腺平均EQD2剂量为7.89 Gy,全乳放疗组为0.23 Gy。

核心结论

  • 乳腺癌锁骨上淋巴结照射后甲状腺功能减退风险增加,而Lv.4区域淋巴结照射未见显著增加。
  • 数据支持在区域淋巴结照射时常规勾画甲状腺,未来需研究最佳剂量体积约束。

研究设计与样本

  • 回顾性研究2007至2016年接受辅助放疗的4073例乳腺癌女性。
  • 按放疗靶区分组:全乳放疗组2468例、Lv.4区域淋巴结照射组215例、锁骨上淋巴结照射组1390例。
  • 辅助分析中每组各200例(共600例)估算甲状腺平均剂量,并转换为α/β=3的EQD2。

主要发现

  • 中位随访84个月;全乳放疗组84个月,Lv.4组44个月,锁骨上淋巴结照射组91个月。
  • 3年甲状腺功能减退发生率:锁骨上淋巴结照射组2.2% vs 全乳放疗组0.8%(Bonferroni校正P<.001)。
  • Lv.4组3年发生率0.9% vs 全乳放疗组0.8%(Bonferroni校正P>.05)。
  • Cox模型调整风险比:锁骨上淋巴结照射 vs 全乳放疗为2.25(95%CI 1.49-3.38),辅助全身治疗为1.69(95%CI 1.12-2.56),年龄<60岁为2.07(95%CI 1.07-3.99)。
  • 甲状腺平均EQD2剂量:全乳放疗组0.23 Gy、Lv.4组1.93 Gy、锁骨上淋巴结照射组7.89 Gy(P<.001);5年局部区域复发率组间无统计学差异(<3%)。

关键数值与推荐

  • 锁骨上淋巴结照射组3年甲状腺功能减退发生率为2.2%,全乳放疗组为0.8%(Bonferroni校正P<.001)。
  • Lv.4区域淋巴结照射组3年发生率为0.9%,与全乳放疗组无显著差异(Bonferroni校正P>.05)。
  • 甲状腺平均EQD2剂量:全乳放疗组0.23 Gy、Lv.4组1.93 Gy、锁骨上淋巴结照射组7.89 Gy(P<.001)。

临床怎么用

  • 乳腺癌行锁骨上淋巴结照射时应关注甲状腺功能减退风险,考虑常规勾画甲状腺。
  • Lv.4区域淋巴结照射的甲状腺功能减退风险与全乳放疗相近。
  • 年龄<60岁及接受辅助全身治疗者甲状腺功能减退风险更高。

局限性

  • Lv.4区域淋巴结照射组样本量较小(215例)且中位随访较短(44个月)。
  • 甲状腺平均剂量仅在每组200例的辅助分析中估算。
  • 原文未报告最佳剂量体积约束。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To study the hypothyroidism risk after adjuvant radiation therapy (RT) and the association of different RT targets with hypothyroidism risk. METHODS: We studied 4073 women treated with adjuvant RT for breast cancer from 2007 to 2016. The primary endpoint was hypothyroidism development after RT. Patients were divided and analyzed into 3 groups: whole breast (WB)-alone (n = 2468), regional node irradiation (RNI)-Lv.4 (n = 215; cranial border at the subclavian artery, according to the European Society for Radiotherapy and Oncology consensus guideline), and RNI-supraclavicular lymph node (SCL) (n = 1390; cranial border at the cricoid cartilage). In general, RNI-Lv.4 was used in the patients with high-risk pN0 and pN1 breast cancer. In auxiliary analysis, the mean thyroid dose was estimated in each group (total n = 600, 200 from each group). All the doses were converted to the equivalent dose in 2 Gy fractions (EQD2) with α/β ratios of 3. RESULTS: The median follow-up duration was 84 months (WB-alone, 84 months; RNI-Lv.4, 44 months; RNI-SCL, 91 months). The 3-year hypothyroidism incidence rate differed significantly between the RNI-SCL and WB-alone groups (2.2% vs 0.8%; Bonferroni corrected P [Pc] < .001) but not between the RNI-Lv.4 and WB-alone groups (0.9% vs 0.8%; Pc > .05). The Cox model revealed an adjusted hazard ratio of 2.25 (95% CI, 1.49-3.38) for RNI-SCL vs WB-alone, 1.69 (95% CI, 1.12-2.56) for adjuvant systemic therapies, and 2.07 (95% CI, 1.07-3.99) for age <60 years. In the subgroup analysis, the hypothyroidism risk became more prominent in patients aged <60 years. The mean exposure doses to the thyroid were 0.23 versus 1.93 versus 7.89 Gy (EQD2) for the WB-alone versus RNI-Lv.4 versus RNI-SCL groups (P < .001). No statistically different locoregional recurrence rates were seen between groups (5-year rate: <3%). CONCLUSIONS: The risk of hypothyroidism increases after RNI-SCL for breast cancer but not after RNI-Lv 4. These data support routine contouring of the thyroid in the RNI setting, and future studies are required to develop optimal dose-volume constraints.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Choi SH, Chang JS, Byun HK, et al. Risk of Hypothyroidism in Women After Radiation Therapy for Breast Cancer. Int J Radiat Oncol Biol Phys. 2021. PMID: 33412261. doi:10.1016/j.ijrobp.2020.12.047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。